Benzinga · Nov 16, 2026
Guggenheim Maintains Buy on ArriVent BioPharma, Lowers Price Target to $28
Guggenheim analyst Michael Schmidt maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $30 to $28.

NASDAQ · AVBP
Healthcare · Biotechnology
$10.90
Up+$0.36 (+3.30%)
Updated Nov 20, 2026, 1:10 AM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · AVBP
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 18, 2026
AVBP closed at $10.90 after 20 trading sessions, down 43.23% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 18, 2026 | $10.44 | $11.11 | $10.33 | $10.90 | 2.7M |
| Nov 17, 2026 | $11.57 | $11.87 | $10.495 | $10.69 | 863.86K |
| Nov 16, 2026 | $12.86 | $13.142 | $11.55 | $11.56 | 644.24K |
| Nov 13, 2026 | $13.00 | $13.24 | $12.592 | $13.01 | 616.14K |
| Nov 12, 2026 | $13.55 | $13.62 | $12.89 | $13.07 | 793.95K |
| Nov 11, 2026 | $13.62 | $13.91 | $13.38 | $13.505 | 911.26K |
| Nov 10, 2026 | $14.25 | $15.05 | $13.21 | $13.49 | 776.3K |
| Nov 9, 2026 | $13.86 | $14.595 | $13.49 | $14.16 | 905.97K |
| Nov 6, 2026 | $12.40 | $13.875 | $12.00 | $13.64 | 1.4M |
| Nov 5, 2026 | $13.39 | $13.50 | $12.18 | $12.23 | 1.1M |
| Nov 4, 2026 | $13.39 | $13.57 | $12.465 | $13.49 | 1.86M |
| Nov 3, 2026 | $13.47 | $13.96 | $13.01 | $13.02 | 1.23M |
| Nov 2, 2026 | $14.89 | $14.99 | $13.255 | $13.35 | 1.24M |
| Oct 30, 2026 | $15.78 | $16.165 | $14.325 | $14.87 | 1.19M |
| Oct 29, 2026 | $15.87 | $16.42 | $15.73 | $15.95 | 658.31K |
| Oct 28, 2026 | $15.67 | $15.885 | $15.20 | $15.73 | 990K |
| Oct 27, 2026 | $15.45 | $15.69 | $15.00 | $15.40 | 1.58M |
| Oct 26, 2026 | $18.14 | $18.16 | $14.78 | $15.36 | 5.95M |
| Oct 23, 2026 | $19.00 | $21.23 | $18.18 | $21.00 | 3.28M |
| Oct 22, 2026 | $18.93 | $19.68 | $18.78 | $19.20 | 843.7K |
The latest Smart Investors Daily articles mentioning AVBP.
Company
Market Activity
Research & News
AVBP research
Company profile and research snapshot.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 16, 2026 | Guggenheim | Buy | — |
| Nov 10, 2026 | Truist Securities | Buy | — |
| Oct 27, 2026 | Guggenheim | Buy | — |
| Oct 20, 2026 | B. Riley Securities | Buy | — |
| Oct 16, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
Benzinga · Nov 16, 2026
Guggenheim analyst Michael Schmidt maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $30 to $28.
Benzinga · Nov 10, 2026
Truist Securities analyst Supawat Thongthip maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $21 to $24.
Yahoo · Nov 9, 2026
Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLCPresented encouraging Phase 1 data for ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies at ESMODosed first patient in U.S. Phase 1a/1b study of ARR-002, a novel dual-target MUC16/NaPi2b tetravalent ADC, with initial focus in ovarian and endometrial cancersStrengthened clinical leadership with announcement of Priti Patel, M.D., M.S., as Chief Medical Officer, bringing extensive oncology development exper
Benzinga · Nov 9, 2026
ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(1.05) by 22.86 percent. This is a 2.41 percent increase over losses of $(0.83) per share
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning AVBP.